secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001125345-24-000091
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q1 net loss $52.2M; interim TAMARACK data shows vobra duo activity in mCRPC
--------------------------------------------------------------------------------

- Q1 net loss $52.2M ($0.84/share) vs $38.0M loss in Q1 2023; total revenue $9.1M, down from $24.5M.
- Cash, equivalents and marketable securities $184.2M as of March 31, 2024; cash runway expected into 2026.
- Interim TAMARACK data: vobra duo 2.0 mg/kg q4W showed confirmed PSA≥50% reduction in 36/82 (43.9%) and ORR of 17.8%.
- Five fatal AEs reported in TAMARACK; two pneumonitis deaths in 2.7 mg/kg cohort; Phase 3 planning initiated for 2025.
- Company plans to expand TAMARACK to NSCLC, SCLC, melanoma and other indications in mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/0001125345-24-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/mgnx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001125345-24-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer